We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just to add that they 2 of these arrangements in place, second is with sanofi. Same numbers but in euros not dollars.
So C4X Discovery Holdings plc received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca PLC, following trials of the C4X respiratory disease therapy treatment. The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November. In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
This share is so undervalued now, so can't wait to top up on my holding ! There does not appear to be a better investment out there except maybe Futura Medical. Perhaps split any available monies between both of these.
I saw the below post by gggg21 , I have to many losing AIM shares , I have read on other BBs that you can not go short on these types of shares , and this one having a smaller free float then others .
What is the truth of shorting on AIM .
RE: So...15 Dec 2023 08:10
Amazing how that one short opened this morning has pushed it down but so difficult to buy.
Up 13% to 17.3p on the bid. 2.9% spread the ask is 17.8p.
Now above my buy price of 16.65p in hindsight the noticed 43% rise two days ago was a buy signal .
Two weeks ago on 18/12/23 I saw a new low of 8.41p ( 50 % down ) must be manipulation this payment was known to be coming ?
Bad luck for any who might of sold a week before Christmas day.
Thanks for sharing.
I concur that this rise is more than just reassurance on funding requirements - it is further validation of the tech, and an important value inflection point. The 3 days of consecutive strong SP rises on heavy trading demonstate that.
With a Sanofi milestone payment imminent and further deals in the pipeline, I expect a big 2024. This was above 40p a couple of years ago. I expect it to rise significantly above that
It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall.
It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease.
Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology.
'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital.
'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.'
https://www.thisismoney.co.uk/money/markets/article-12930315/SMALL-CAP-MOVERS-C4X-Discovery-cashes-deal-pharma-giant.html
Still got a lot higher to go though, thats my view anyway...gla
"It's dollars not £s"
It's $s and €s - not £s.
Lombard is simply risk managing their investment after a decent rise...it's common amongst fund managers...
either way, the pharma sector's on the turn at last so bullishness is returning to a battered sector
If they are still selling, it's getting snapped up. This doesn't half shoot due to the small free float. My average of 24p now within sight
Don't know why Lombard sold yesterday,
looking good though
Before the next news and next leg up ?
Looks like they are still selling
Going to be a lot of good sessions ahead as it heads to over 1.20 and beyond
GLA
Nice rise today
Some sanity has returned.
**UP TO** AND **POTENTIAL** - thus there's a chance they don't get anything more.
Who knows what they are up to, they've increased their holding by 2% in the last few months and sold .5% today....
Anyone know if they’ll be selling more? Thanks
For the sp today, hoping for a few more in the coming days/weeks....our valuation is too cheap for our connections, projects and cash balance to those across the pond ....gla
The market potential in immuno-inflammation is large and growing, reflecting the need for better treatments. With a robust balance sheet, focused strategy and streamlined portfolio, we believe we are strongly positioned in immuno-inflammation and excited about the future.
On the out-licensed programme, the company noted that Sanofi is making progress on the IL-17A inhibitor programme for inflammatory diseases towards the next milestone.
Of its portfolio of early-stage discovery immuno-inflammatory molecules, the board still anticipates moving two projects into lead optimisation by the end of 2024, following the project initiation process assessment involving C4X’s proprietary platforms, Conformetrix and PatientSeek, together with a thorough analysis of the commercial viability.
PatientSeek was launched in February to optimise patient selection, with the potential to match the most effective treatments with groups of patients who are most likely to benefit thereby ensuring the right drug is given to the right patient, based on their genetics.
Earl, loving your enthusiasm, but in the interests of accuracy, mention of further payments from Astra Zeneca and Sanofi should be preceded by the words UP TO
It's dollars not £s
Add C4XD
AstraZeneca already paid £11m
£405m still in the pipeline
plus Sanofi £404m still to come
mcap £30m
has anyone seen yesterday
Not pump..... this is in the rns....
$810m payments lined up for C4XD from AstraZeneca and Sanofi
Read Rns